MedTrace Logo

Treatment of Actinic Keratoses of the Face With Imiquimod 3.75% Cream Followed by Photodynamic Therapy

NCT01203878 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2014-12-08

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to explore the effect of treating actinic keratoses of the face with imiquimod 3.75% cream followed by photodynamic therapy in comparison to treatment with imiquimod alone

Conditions

  • Actinic Keratosis

Interventions

DRUG

Photodynamic therapy

Administered 4 weeks after completion of imiquimod therapy

DRUG

Imiquimod

Imiquimod 3.75% cream, up to 2 packets, applied topically daily for two 2-week cycles separated by a no-treatment interval of 2-weeks, followed observation

Sponsors & Collaborators

  • Graceway Pharmaceuticals, LLC

    collaborator INDUSTRY

  • Tennessee Clinical Research Center

    lead OTHER

Principal Investigators

  • Michael Gold, MD · Tennessee Clinical Research Center

  • Joel Cohen, MD · AboutSkin Dermatology and DermSurgery, PC

  • Girish Munavalli, MD · Dermatology, Laser & Vein Specialists of the Carolinas

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-09-30
Primary Completion
2011-11-30
Completion
2011-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01203878 on ClinicalTrials.gov